Market closedNon-fractional
Aclaris Therapeutics/ACRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Aclaris Therapeutics
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Ticker
ACRS
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Wayne, United States
Employees
89
Website
www.aclaristx.com
ACRS Metrics
BasicAdvanced
$82M
Market cap
-
P/E ratio
-$1.09
EPS
0.24
Beta
-
Dividend rate
Price and volume
Market cap
$82M
Beta
0.24
Financial strength
Current ratio
6.74
Quick ratio
6.401
Long term debt to equity
2.092
Total debt to equity
2.446
Management effectiveness
Return on assets (TTM)
-31.90%
Return on equity (TTM)
-48.47%
Valuation
Price to revenue (TTM)
2.619
Price to book
0.58
Price to tangible book (TTM)
0.58
Price to free cash flow (TTM)
-1.106
Growth
Revenue change (TTM)
0.95%
Earnings per share change (TTM)
-24.43%
3-year revenue growth
65.60%
3-year earnings per share growth
-8.68%
What the Analysts think about ACRS
Analyst Ratings
Majority rating from 9 analysts.
ACRS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.3M
-86.86%
Net income
-$17M
1,107.14%
Profit margin
-734.78%
9,084.75%
ACRS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.42
-$0.41
-$0.02
-$0.24
-
Expected
-$0.45
-$0.48
-$0.34
-$0.29
-$0.20
Surprise
-6.67%
-14.58%
-94.19%
-16.00%
-
ACRS News
AllArticlesVideos
Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)
GlobeNewsWire·2 weeks ago
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewsWire·4 weeks ago
American Clinical Research Services Announces Strategic Acquisition of Elixia
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aclaris Therapeutics stock?
Aclaris Therapeutics (ACRS) has a market cap of $82M as of July 06, 2024.
What is the P/E ratio for Aclaris Therapeutics stock?
The price to earnings (P/E) ratio for Aclaris Therapeutics (ACRS) stock is 0 as of July 06, 2024.
Does Aclaris Therapeutics stock pay dividends?
No, Aclaris Therapeutics (ACRS) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Aclaris Therapeutics dividend payment date?
Aclaris Therapeutics (ACRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Aclaris Therapeutics?
Aclaris Therapeutics (ACRS) has a beta rating of 0.24. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Aclaris Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.